Thomas Theriault
Gründer bei Bullet Biotechnology, Inc.
Profil
Thomas Theriault is the Chief Scientific Officer and founder of Bullet Biotechnology, Inc. which is founded in 2011.
He held the position of Vice President-Research at Incyte Corp.
from 1996 to 2004 and Vice President-Research & Development at Genitope Corp.
from 2005 to 2008.
Dr. Theriault received his undergraduate degree from Dartmouth College and his doctorate from Stanford University.
Dr. Theriault is also the founder of Combion, Inc. which does not have a founding date available.
Aktive Positionen von Thomas Theriault
| Unternehmen | Position | Beginn |
|---|---|---|
Bullet Biotechnology, Inc.
 Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Gründer | 01.09.2011 |
Ehemalige bekannte Positionen von Thomas Theriault
| Unternehmen | Position | Ende |
|---|---|---|
| GENITOPE CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 31.03.2008 |
| INCYTE CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2004 |
Combion, Inc.
 Combion, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Incyte Corp., Combion, Inc. is a company that develops ink-jet technology for a variety of high-density gridding synthesis applications. The company is based in Pasadena, CA. The company was founded by Thomas Theriault, John D. Baldeschwieler. Combion was acquired by Incyte Corp. on August 15, 1996 for $2.98 million. | Gründer | 01.01.1996 |
Ausbildung von Thomas Theriault
| Dartmouth College | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Genitope Corp.
 Genitope Corp. BiotechnologyHealth Technology Genitope Corp. operates as a biotechnology company, which focuses on the research and development of novel immunotherapies for the treatment of cancer. The company was founded on August 15, 1996 and is headquartered in Redwood, CA. | Health Technology |
Combion, Inc.
Combion, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Incyte Corp., Combion, Inc. is a company that develops ink-jet technology for a variety of high-density gridding synthesis applications. The company is based in Pasadena, CA. The company was founded by Thomas Theriault, John D. Baldeschwieler. Combion was acquired by Incyte Corp. on August 15, 1996 for $2.98 million. | Commercial Services |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Health Technology |